

## Dysmenorrhea

[View the current Dysmenorrhea InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Dysmenorrhea.html>) - Regularly Updated.

Dysmenorrhea, cramps or painful menstruation, involves menstrual periods that are accompanied by either sharp, intermittent pain or dull, aching pain, usually in the calves, pelvis or lower abdomen. Many young swimmers experience menstrual cramps due to their body structure. The body structure is unable to be altered. Side effects may include nausea, headaches, or extreme pain within the next couple days. Main causes are due to the body structure, deep water, and extreme coldness; this will also cause the person to be inflexible. Painful menstruation affects approximately 50% of menstruating women, and 10% are incapacitated for up to 3 days. Painful menstruation is the leading cause of lost time from school and work among women of childbearing age. This pain may precede menstruation by several days or may accompany it, and it usually subsides as menstruation tapers off. Although some pain during menstruation is normal, excessive pain is not. Dysmenorrhea refers to menstrual pain severe enough to limit normal activities or require medication. It may coexist with excessively heavy blood loss. \*Primary dysmenorrhea refers to menstrual pain that occurs in otherwise healthy women. This type of pain is not related to any specific problems with the uterus or other pelvic organs. \*Secondary dysmenorrhea is menstrual pain that is attributed to some underlying disease process or structural abnormality either within or outside the uterus. Endometriosis is the most common cause of dysmenorrhea associated with a disease process and is frequently misdiagnosed. The incidence of menstrual pain is greatest in women in their late teens and 20s, then declines with age. Some women experience increased menstrual pain in their late 30s and 40s as their endocrine systems prepare for menopause by decreasing hormone levels and thus fertility. It does not appear to be affected by childbearing. An estimated 10 percent to 15 percent of women experience monthly menstrual pain severe enough to prevent normal daily function at school, work, or home. ([From the Wikipedia article Dysmenorrhea.](#))

### Recent Publications on Dysmenorrhea:



- [Efficacy of Gonadotropin-Releasing Hormone Agonist and an Extended-Interval Dosing Regimen in the Treatment of Patients with Adenomyosis and Endometriosis.](#)  
*Aims: To determine the effects of gonadotropin-releasing hormone agonist...*20th November, 2009  
Department of Obstetrics and Gynecology, First Municipal Hospital- Gynecol Obstet Invest. 2009 Nov 17;69(2):73-77. ([DOI Direct Link](#))
- [Thrombospondin-1 serum levels do not correlate with pelvic pain in patients with ovarian endometriosis.](#)  
*ABSTRACT: Objective: Thrombospondin-1 serum levels is correlate with pelvic...*18th November, 2009  
- J Ovarian Res. 2009 Nov 16;2(1):18. ([DOI Direct Link](#))
- [Endometriosis in Italy: from cost estimates to new medical treatment.](#)  
*Endometriosis is defined as the presence of endometrial-like tissue...*17th November, 2009  
Division of Obstetrics and Gynecology, Department of Pediatrics,- Gynecol Endocrinol. 2009 Nov;25(11):734-40.
- [Effect of peritoneal fluid from endometriosis patients on neuroblastoma cells in culture.](#)

- AIM: Endometriosis is often associated with lower abdominal pain,...*17th November, 2009  
Department of Obstetrics/Gynaecology, University of Berne, Berne,- Gynecol Endocrinol. 2009  
Nov;25(11):707-12.
- [\[Clinical practice guidelines. Diagnosis and treatment of primary dysmenorrhea in teenagers\]](#)  
*AIM: Endometriosis is often associated with lower abdominal pain,...*12th November, 2009  
Clinica para la Atencion de la Paciente Adolescente del Instituto Nacional- Ginecol Obstet Mex. 2009  
Aug;77(8):S211-29.
  - [Efficacy of Bipolar Radiofrequency Endometrial Ablation vs Thermal Balloon Ablation for Management of Menorrhagia: A Population-Based Cohort.](#)  
*STUDY OBJECTIVE: To compare the efficacy of bipolar radiofrequency...*10th November, 2009  
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester,- J Minim Invasive Gynecol. 2009  
Nov-Dec;16(6):692-9. ([DOI Direct Link](#))
  - [Uterus didelphys with unilateral obstructed hemivagina with hematometrocolpos and hematosalpinx with ipsilateral renal agenesis.](#)  
*Uterus didelphys with blind hemivagina and ipsilateral renal agenesis...*3rd November, 2009  
Department of Radiodiagnosis, Sardar Patel Medical College, Bikaner,- J Hum Reprod Sci. 2009  
Jul;2(2):87-9. ([DOI Direct Link](#))
  - [Management of Primary Dysmenorrhea by School Adolescents in ILE-IFE, Nigeria.](#)  
*Dysmenorrhea is a problem that girls and women face and often manage...*24th October, 2009  
- J Sch Nurs. 2009 Oct 22. ([DOI Direct Link](#))
  - [Complementary and alternative medications for women's health issues.](#)  
*Women often seek alternative treatment options such as herbs, dietary...*21st October, 2009  
Auburn University Harrison School of Pharmacy, 2155D Walker Building,- Nutr Clin Pract. 2009  
Oct-Nov;24(5):589-608. ([DOI Direct Link](#))
  - [The unicornuate uterus with an occult adenomyotic rudimentary horn.](#)  
*We report 2 case of an atypical variant of unicornuate uterus in 2...*20th October, 2009  
Department of Obstetrics, Gynecology and Neonatology, Fondazione- J Minim Invasive Gynecol. 2009  
Sep-Oct;16(5):622-5. ([DOI Direct Link](#))
  - [Endometriosis and mechanisms of pelvic pain.](#)  
*Endometriosis remains an enigmatic disorder in that the cause, the natural...*20th October, 2009  
Department of Obstetrics and Gynecology, University of Rochester School of- J Minim Invasive  
Gynecol. 2009 Sep-Oct;16(5):540-50. ([DOI Direct Link](#))
  - [Cornual pregnancy as a complication of the use of a levonorgestrel intrauterine device: a case report.](#)  
*INTRODUCTION: Complications of copper load intrauterine devices, including...*16th October, 2009  
Medisch Centrum Haaglanden, Department of Obstetrics and Gynaecology- J Med Case Reports.  
2009 Jul 22;3:8387. ([DOI Direct Link](#))
  - [Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study.](#)  
*BACKGROUND This pilot study evaluates the efficacy of norethisterone...*13th October, 2009  
Department of Obstetrics and Gynaecology, San Martino Hospital and- Hum Reprod. 2009 Oct 10. ([DOI Direct Link](#))
  - [Safety and tolerability of short-term preventive frovatriptan: a combined analysis.](#)  
*OBJECTIVE: To assess the safety and tolerability profile of the...*1st October, 2009  
The City of London Migraine Clinic, London, UK.- Headache. 2009 Oct;49(9):1298-314. ([DOI Direct Link](#))
  - [Cellular transport of anti-inflammatory pro-drugs originated from a herbal formulation of Zingiber cassumunar and Nigella sativa.](#)  
*ABSTRACT: BACKGROUND: The rhizome of Zingiber cassumunar and the seed of...*29th September, 2009  
Department of Pharmacognosy, Faculty of Pharmacy, Mahidol University,- Chin Med. 2009 Sep  
25;4:19. ([DOI Direct Link](#))

## BioNews Results for Dysmenorrhea

- [Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results](#)  
*Entrepreneur.com: Nov 13 2009 7:39PM Matching: dysmenorrhea*
- [Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results](#)  
*Therapeutics Daily: Nov 12 2009 2:49PM Matching: dysmenorrhea*
- [Biostar Pharmaceuticals reports financial results for the third quarter of 2009](#)  
*News-Medical.Net: Nov 12 2009 2:46PM Matching: dysmenorrhea*
- [Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results](#)  
*Street Insider: Nov 12 2009 1:34PM Matching: dysmenorrhea*
- [Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results](#)  
*Yahoo! Canada: Nov 12 2009 1:13PM Matching: dysmenorrhea*
- [PDC Biotech Raises 4 Million](#)  
*Private Equity HUB: Nov 2 2009 1:52PM Matching: dysmenorrhea*
- [PDC Biotech GmbH Announces Close of Series A Financing](#)  
*b3c Newswire: Oct 30 2009 3:53PM Matching: dysmenorrhea*
- [PDC Biotech GmbH Announces Close of Series A Financing](#)  
*Biotech Intelligence: Oct 30 2009 11:13AM Matching: dysmenorrhea*
- [My five-year-old has cancer](#)  
*Philippine Daily Inquirer: Oct 20 2009 9:46PM Matching: dysmenorrhea*

## Dysmenorrhea Patents:



- 7534914- [Substituted methyl aryl or heteroaryl amide compounds](#)
- 7563797- [Substituted imidazo\(1,2-A\)pyrimidines and imidazo\(1,2-A\) pyridines as cannabinoid receptor ligands](#)
- 7566739- [Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists](#)
- 7569364- [Anti-NGF antibodies and methods using same](#)
- 7569384- [Albumin fusion proteins](#)
- 7569570- [Thienopyrimidines, process for preparing the same and use thereof](#)
- 7569572- [Pyrazolo\[4,3-D\]pyrimidines](#)
- 7569601- [Cycloalkylidene compounds as modulators of estrogen receptor](#)
- 7569602- [Furan derivatives as EP.sub.4 receptor antagonists](#)
- 7572797- [Amino substituted pyrazine derivatives for the treatment of pain](#)
- 7572799- [Pyrazolo\[4,3-d\]pyrimidines as Phosphodiesterase Inhibitors](#)
- 7560589- [Cycloalkylidene compounds as modulators of estrogen receptor](#)
- 7560464- [Polycyclic pyrimidines as potassium ion channel modulators](#)
- 7557136- [Pyrrolidine derivatives as oxytocin antagonists](#)
- 7538107- [Oxazinan-2-one derivatives useful as PR modulators](#)
- 7544805- [Stable amorphous forms of montelukast sodium](#)
- 7547717- [Ion channel modulators](#)
- 7550451- [Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy](#)

- [7550462- Piperazinediones as oxytocin receptor antagonists](#)
- [7550497- Phosphoramidate derivatives](#)
- [7550569- Antibodies that specifically bind to GMAD](#)
- [7553853- Solid-state montelukast](#)
- [7553973- Pharmaceutical compounds](#)
- [7557134- N-\(heteroaryl\)-1H-indole-2-carboxamide derivatives and their use as vanilloid TRPV.sub.1 receptor ligands](#)
- [7576129- Carboxylic acid compounds](#)
- [7579468- Methods of modulating neurotrophin-mediated activity](#)
- [7605122- Human chorionic gonadotropin \(hCG\) formulations for facilitating weight loss and body contouring](#)
- [7608628- Alkylsulphonamide quinolines](#)
- [7608712- Pyridine imidazoles and aza-indoles as progesterone receptor modulators](#)
- [7612114- Selective estrogen receptor modulator](#)
- [7612226- Amino acid derivatives](#)
- [7618639- Synergistic phytoceutical compositions](#)
- [7618979- Pyridopyrrolizine and pyridoindolizine derivatives](#)
- [7618987- Acylated piperidine derivatives as melanocortin 4-receptor agonists](#)
- [7618989- Tricyclic oxazolidone derivatives useful as PR modulators](#)
- [7618990- Oxazolidone derivatives as PR modulators](#)
- [7598397- Sulfonamide peri-substituted bicyclics for occlusive artery disease](#)
- [7598237- 7-aryl 1,5-dihydro-4,1-benzoxazepin-2\(3H\)-one derivatives and their use as progesterone receptor modulators](#)
- [7595409- 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers](#)
- [7582653- Mercaptophenyl naphthyl methane compounds and synthesis thereof](#)
- [7582671- Therapeutic use of N-\(1H-indolyl\)-1H-indole-2-carboxamide derivatives](#)
- [7582745- Compositions and methods for inhibiting expression of Nav1.8 gene](#)
- [7585977- Selective estrogen receptor modulators containing a phenylsulfonyl group](#)
- [7589123- Chemical compounds](#)
- [7589124- Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use](#)
- [7589206- Pyrrolopyridine derivatives](#)
- [7589233- L-Threonine derivatives of high therapeutic index](#)
- [7592010- Albumin fusion proteins](#)
- [7593952- Enhanced medical treatment system](#)
- [7618994- Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

